. 2015 Aug 6;9:4389–4396. doi: 10.2147/DDDT.S62778

Table 2.

Summary of studies assessing the use of aflibercept in the treatment of diabetic macular edema

Study	Study design	Year	Sample size (patients)	VA (letters) study eye	CMT (µm) study eye
Da Vinci (Phase II)75	Multicenter, randomized, double masked, active controlled	2012
0.5q4			44	11.0^a	−165.4^a
2q4			44	13.1^a	−227.4^a
2q8			42	9.7^a	−187.8^a
2PRN			45	12.0^a	−180.3^a
Control^b			44	2.5	−58.4
VISTA (Phase III)76	Multicenter, randomized, double masked, active controlled	2014
2q4			154	12.5±9.5^a	−185.9±150.7^a
2q8			151	10.7±8.2^a	−183.1±153.5^a
Control^b			154	0.2±12.5	−73.3±176.7
VIVID (Phase III)76	Multicenter, randomized, double masked, active controlled	2014
2q4			136	10.5±9.5^a	−195.0±146.6^a
2q8			135	10.7±9.3^a	−192.4±149.9^a
Control^b			132	1.2±10.6	−66.2±139.0
Protocol T (Phase III)5	Multicenter, randomized, single masked (subject)	2015
2q4			224	13.3	−169±138
Bevacizumab			218	9.7	−101±121
Ranibizumab (0.3 mg)			218	11.2	−147±134

Notes:

P<0.05 compared to control arm;

macular laser photocoagulation; 0.5q4–0.5 mg aflibercept; every 4 weeks; 2q4–2 mg aflibercept every 4 weeks; 2q8–2 mg aflibercept every 8 weeks following three loading doses; PRN – aflibercept pro re nata following three loading doses.

Abbreviations: VA, visual acuity; CMT, central macular thickness.